Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. FBRX
FBRX logo

FBRX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Forte Biosciences Inc (FBRX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
28.270
1 Day change
1.04%
52 Week Range
35.620
Analysis Updated At
2026/03/06
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Forte Biosciences Inc (FBRX) is not a strong buy for a beginner investor with a long-term focus at this time. The stock lacks positive catalysts, has weak financial performance, and shows no significant trading trends or signals. Additionally, technical indicators are neutral, and the options data suggests limited trading sentiment. Given the investor's profile and the lack of compelling reasons to invest immediately, holding off on this stock is recommended.

Technical Analysis

The MACD histogram is positive at 0.0492, but contracting, indicating weakening momentum. RSI is neutral at 51.319, showing no clear overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock's recent price change (-4.66%) and projected short-term trends (-0.96% next day, -1.7% next week, -7.82% next month) suggest limited upside potential. Key support is at 27.511, and resistance is at 32.187.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
9
Buy
3

Positive Catalysts

  • NULL identified. No recent news or significant insider/hedge fund activity. Technical indicators are neutral, and there are no strong trading signals.

Neutral/Negative Catalysts

  • Weak financial performance with negative net income (-$17.68M) and declining EPS (-78.19% YoY). No recent congress trading data or significant trading sentiment. Projected short-term price trends are negative.

Financial Performance

In Q3 2025, the company reported zero revenue growth (0% YoY) and a net income loss of -$17.68M, though this improved by 110.70% YoY. EPS dropped significantly (-78.19% YoY), and gross margin remained at 0%. Overall, the financials indicate poor performance with no clear growth trajectory.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes provided. Wall Street sentiment and coverage appear limited, indicating low interest in the stock.

Wall Street analysts forecast FBRX stock price to rise
2 Analyst Rating
Wall Street analysts forecast FBRX stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 27.980
sliders
Low
65
Averages
65
High
65
Current: 27.980
sliders
Low
65
Averages
65
High
65
Evercore ISI
Outperform
initiated
$65
AI Analysis
2025-11-25
Reason
Evercore ISI
Price Target
$65
AI Analysis
2025-11-25
initiated
Outperform
Reason
Evercore ISI initiated coverage of Forte Biosciences with an Outperform rating and $65 price target. There has been a notable re-rating in development-stage microcap companies, especially those with important proof of concept data in 2025 and 2026, notes the analyst. While arguing that Forte "falls squarely in this bucket," the firm notes shares have been slow to get the same bid until the last two weeks, adding that it thinks the setup is "super attractive into a catalyst-rich 2026."
Guggenheim
NULL -> Buy
initiated
$75
2025-08-18
Reason
Guggenheim
Price Target
$75
2025-08-18
initiated
NULL -> Buy
Reason
Guggenheim initiated coverage of Forte Biosciences with a Buy rating and $75 price target.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for FBRX
Unlock Now

People Also Watch